RLAY · Relay Therapeutics

The thesis

Relay Therapeutics is a clinical-stage cancer drug developer whose value rests on one molecule, zovegalisib (also called RLY-2608). The 4 November 2026 third-quarter report moved the case forward: cash of $848.6 million funds operations into 2029, and the company estimates enrollment in its Phase 3 ReDiscover-2 breast-cancer trial will complete in mid-2027. The 14 December 2026 ASH presentation, the year-end regulatory update on the first-line trial, and any share issuance settle what comes next.

The shares closed at $19.94 on 10 November 2026, 3.9% below the 52-week high of $20.75 (adjusted daily closes). The close was $19.69 on 28 October 2026, so the report moved the shares by little.

The story is well known: the story is well known, and since the analyst initiations of 8 July 2026 and 16 July 2026 the new facts have been incremental. The next hard clinical readout is in 2027, so the shares trade on trial-execution milestones, cash and share supply.

The rating moves from low to medium on the report. Enrollment is guided earlier than the company's own earlier benchmarks and the runway held. The share-supply questions from August are still open.

Bullish and bearish views on Relay Therapeutics, Inc.

The bull case on Relay Therapeutics, Inc. (RLAY), in brief: cash funds the program into 2029. The bear case: one molecule carries the company.

Bull case

• Cash funds the program into 2029. Relay reported $848.6 million of cash, cash equivalents and investments at 30 September 2026, against $910.9 million at 30 June 2026, and said it covers operating needs into 2029 (Q3 2026 release, 4 November 2026). The runway is management's forecast.
• Enrollment is moving faster than expected. The release estimates ReDiscover-2 enrollment completes in mid-2027, which the company describes as about a year sooner than recent benchmarks. The release gives a completion date rather than a patient count.
• Breast-cancer data and regulatory standing. The FDA granted zovegalisib Breakthrough Therapy designation in February 2026. Relay's 16 March 2026 presentation reported median progression-free survival of 11.1 months for zovegalisib plus fulvestrant at the Phase 3 dose.
• A second indication reports in December. Updated ReInspire vascular-anomalies data are scheduled as an oral presentation at the American Society of Hematology (ASH) meeting on 14 December 2026, with a company call the same day (Q3 release). Relay reported on 19 May 2026 that 60% of patients had a volumetric response at 12 weeks.
• Analyst targets sit well above the price. Jones Trading maintained a Buy and raised its target to $31 on 7 November 2026 (company news headline). Benzinga lists JPMorgan at $31 from 14 August 2026. Canaccord Genuity's target was $29 on 16 July 2026.
• The partnered drug gained approval. The FDA granted full approval to lirafugratinib (Lyrfigtu), licensed to Elevar Therapeutics, and the NCCN added it to its guidelines on 3 November 2026. Relay recorded no license revenue in the third quarter and $3.4 million over nine months of 2026 (Q3 release).

Bear case

• One molecule carries the company. The breast-cancer, vascular-anomalies and planned first-line programs all rest on zovegalisib. A safety or efficacy problem would hit every program at once.
• Cash is falling. Cash fell from $910.9 million at 30 June 2026 to $848.6 million at 30 September 2026. The third-quarter net loss was $81.7 million, or $0.37 per share, against $74.1 million a year earlier. Research and development expense was $77.1 million, up from $68.3 million, partly from costs of ending a Cambridge lease (Q3 release).
• Share issuance remains possible. The 6 August 2026 prospectus supplement expanded the at-the-market equity program to $462,978,049. The Q3 release as reviewed does not mention use of the program, and sales need no separate announcement.
• A large holder sold at $19.40. SVF Pauling, a director-affiliated 10% owner, sold 6,000,000 shares at $19.40 on 25 August 2026 (SEC Form 4 filed 28 August 2026). The last close of $19.94 is above that price.
• The price barely reacted to good news. The three-month price change is 0.1% and the shares sit 3.9% under the 52-week high of $20.75, so a gap to the $31 targets rests on trial outcomes still ahead.

Price setup

The reference close on 10 November 2026 was $19.94. The 52-week high of $20.75 is 3.9% above it. The 14-day relative strength index, a 0-to-100 momentum gauge, reads 57.7, down from 66.7 on 28 October 2026, so the shares are no longer near the 70 level read as stretched. The three-month price change is 0.1%.

The price shows the low of the recent slide at $17.30, the close on 15 October 2026. That is the level the case rests on. The area around $19.40 to $20.75 holds the August large-holder sale price and the 52-week high, and a close above $20.75 would be a new 52-week high.

Crowding evidence is mixed. Earnings are behind the shares, so no report falls in the next few weeks. Heavy supply risk comes from the expanded at-the-market program, the August block sale and recurring executive sales under 10b5-1 plans, which are pre-arranged selling schedules.

Catalysts ahead

• 14 December 2026: ReInspire oral presentation at ASH (abstract 878) and company call. Tests whether the early vascular-anomalies response seen in May holds in a larger data set.
• 31 December 2026: Year-end deadline for regulatory update confirming the first-line zovegalisib plus atirmociclib Phase 3 design. Confirms the path to the early-2027 Phase 3 start that widens the program.

Elapsed catalysts

• ~14 November 2026 (est.): Form 10-Q for the third quarter. Would quantify any sales under the at-the-market equity program since the August expansion. (passed)

What would change the view

A daily close below $17.30, the 15 October 2026 close and the low of the October slide. A formal delay of ReDiscover-2 enrollment beyond mid-2027, or new safety or efficacy problems with zovegalisib, would also break the case.

The risks this note tracks, each with what would confirm it:

• ReDiscover-2 enrollment slips past the mid-2027 estimate. Confirmed by: a company statement moving the enrollment completion date beyond mid-2027.
• Company share issuance adds to supply already created by the large-holder sale. Confirmed by: the third-quarter 10-Q or a later filing shows sales under the at-the-market program expanded on 6 August 2026.
• A single-molecule dependency exposes every program to one safety or efficacy setback. Confirmed by: new safety, efficacy or trial-hold disclosure for zovegalisib, including at the 14 December 2026 ASH presentation.
• Further large-holder selling caps the shares near the $19.40 August sale price. Confirmed by: a new SEC Form 4 from SVF Pauling reporting additional sales.

What it trades with

Relay trades with small and mid-cap oncology developers and with the broader biotech index, which respond to interest-rate moves and sector funding. No peer comparison or correlation figure is quoted here. Its own news flow, mainly trial milestones and equity-supply events, has driven the shares in 2026 more than other sectors.